Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933904 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
A Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT03933904: Active Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric, sponsored by University of Pennsylvania.
NCT03933904 is a Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03933904, a Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
Primary Outcome
Clinical Benefit Response (CBR): The CBR was defined by improvements in clinical symptoms such as fatigue, anorexia, fever, and night sweats.6 Laboratory markers such as hemoglobin levels and weight change were also included in the CBR criteria (Table 1). A CBR was considered positive if there was at least a 25% reduction in the size of the largest lymph node (measured by modified Cheson criteria), a significant improvement in at least one laboratory marker (e.g., hemoglobin), and improvement in
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (2)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03933904 still lists
NCT03933904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Castleman Disease appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT03933904 reports a single indexed study location in Arkansas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03933904 about?
NCT03933904 is a clinical study titled "Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease". The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
What is the current status of trial NCT03933904?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-09-25. Estimated completion is 2026-06-30.
What conditions does trial NCT03933904 study?
This clinical trial studies the following conditions: Castleman Disease, Castleman's Disease, Multicentric.
What interventions are being tested in trial NCT03933904?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT03933904?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933904 being conducted?
This trial has 2 study locations across Arkansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castleman Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03933904's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI